Efficacy News and Research

RSS

One dose of mRNA vaccine reduced COVID risk for at least four months in health care workers

A new study compared the efficacy of mRNA vaccines against the original strain of the SARS-CoV-2 and SARS-CoV-2 VoCs among HCWs in Quebec after receiving their first and second doses.

26 Jul 2021

CDC study on efficacy of mRNA vaccines against symptomatic COVID-19

A new study posted to the medRxiv* preprint server derives measures of substantial efficacy for these vaccines in preventing mild to moderate COVID-19 from a group of outpatients with and without a history of vaccination.

26 Jul 2021

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

Researchers from the Institute of Process Engineering of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy.

26 Jul 2021

More popular type of antihypertensive drugs causes slightly more side effects

Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, but the more popular type causes slightly more side effects, finds a multinational observational study led by researchers at Columbia University Vagelos College of Physicians and Surgeons.

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Brain’s locus coeruleus may be a sophisticated regulator of learning and behavior

Small and seemingly specialized, the brain's locus coeruleus (LC) region has been stereotyped for its outsized export of the arousal-stimulating neuromodulator norepinephrine.

26 Jul 2021

Rosin soap as a potential SARS-CoV-2 disinfectant

In a research paper recently uploaded to the preprint server bioRxiv* by Bell et al. (July 19th, 2021), the potential of rosin soap as a virucide is investigated, finding a ten-thousand-fold drop in infectivity against enveloped viruses such as influenza and SARS-CoV-2 in particular.

26 Jul 2021

Activation of integrins by SARS-CoV-2 may be key to infection

A new study describes the key role of membrane proteins called integrins, which are present in epithelia, in the entry and propagation of SARS-CoV-2.

25 Jul 2021

Novel therapeutic agent could be effective for treating cancers with certain gene mutations

Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.

23 Jul 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Facing headwinds on new Alzheimer’s drug, Biogen launches controversial campaign

Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you?

23 Jul 2021

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.

From Aptamer Group 23 Jul 2021

First dose of Pfizer-BioNTech or Oxford-AstraZeneca vaccines has strong protective effect against COVID-19 in older adults

A new study estimates vaccine effectiveness against COVID-19 mortality in England using the RDD approach.

22 Jul 2021

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

A new study characterizes the functional humoral immunity post-COVID-19 mRNA-based vaccination.

22 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Cell-analysis method could pave the way for new vaccine strategies against tuberculosis

A new method that analyzes how individual immune cells react to the bacteria that cause tuberculosis could pave the way for new vaccine strategies against this deadly disease, and provide insights into fighting other infectious diseases around the world.

22 Jul 2021

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

A nationwide case-control study conducted in France has assessed the efficacy of mRNA-based coronavirus disease 2019 (COVID-19) vaccines against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, including B.1.1.7, B.1.351, and P1.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

Pfizer vaccine and isolation independently associated with reduced household transmission of SARS-CoV-2

Israel was among the leading proponents of COVID-19 vaccination as the way out of the current worldwide restrictions on social and economic interactions and activity. A new study, recently released as a preprint on the medRxiv* server, reports on the effects of the large-scale vaccination campaigns carried out in this country, relating to successful control of SARS-CoV-2 spread within households.

22 Jul 2021

Efficacy News and Research

One dose of mRNA vaccine reduced COVID risk for at least four months in health care workers

CDC study on efficacy of mRNA vaccines against symptomatic COVID-19

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

More popular type of antihypertensive drugs causes slightly more side effects

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

Brain’s locus coeruleus may be a sophisticated regulator of learning and behavior

Rosin soap as a potential SARS-CoV-2 disinfectant

Activation of integrins by SARS-CoV-2 may be key to infection

Novel therapeutic agent could be effective for treating cancers with certain gene mutations

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

Clinical trials during a pandemic – lessons from COVID-19

Facing headwinds on new Alzheimer’s drug, Biogen launches controversial campaign

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

First dose of Pfizer-BioNTech or Oxford-AstraZeneca vaccines has strong protective effect against COVID-19 in older adults

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Cell-analysis method could pave the way for new vaccine strategies against tuberculosis

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Pfizer vaccine and isolation independently associated with reduced household transmission of SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News